cGAS-STING signaling pathway in lung cancer: Regulation on antitumor immunity and application in immunotherapy

Chin Med J Pulm Crit Care Med. 2024 Dec 12;2(4):257-264. doi: 10.1016/j.pccm.2024.11.001. eCollection 2024 Dec.

Abstract

The innate immune system has a primary role in defending against external threats, encompassing viruses, bacteria, and fungi, thereby playing a pivotal role in establishing robust protection. Recent investigations have shed light on its importance in the progression of tumors, with a particular emphasis on lung cancer. Among the various signaling pathways implicated in this intricate process, the cGAS-STING pathway emerges as a significant participant. Cyclic GMP-AMP synthase (cGAS) discerns free DNA and activates the stimulator of interferon genes (STING), subsequently culminating in the secretion of cytokines and exerting inhibitory effects on tumor development. Consequently, researchers are increasingly interested in creating anticancer drugs that specifically target the cGAS-STING pathway, offering promising avenues for novel therapeutic interventions. The objective of this review is to present a comprehensive overview of the ongoing research on the cGAS-STING signaling pathway within the realm of lung cancer. The primary emphasis is on understanding its involvement in lung cancer development and assessing its viability as a target for innovative therapeutic options.

Keywords: Cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING); Lung cancer; Tumor microenvironment.

Publication types

  • Review